Compare Novo Nordisk A/S (NVO) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Prologis Inc — how do they compare? Novo Nordisk A/S trades at $45.98 (market cap $207.85B), while Prologis Inc trades at $139.28 (market cap $132.57B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | PLD | |
|---|---|---|
Market Cap | $207.85B | $132.57B |
Sector | Health | Real Estate |
52-Week High | $63.98 | $149.96 |
52-Week Low | $35.29 | $104.81 |
Enterprise Value | $222.55B | $167.31B |
Dividend Yield | 3.81% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Prologis (PLD) trades at $138.73, down 1.02% today, with a bearish technical signal from moving averages but strong fundamentals including a 45.79% net income margin and consistent earnings beats. Recent news highlights a major acquisition of SEGRO for $18.8 billion, expanding its European footprint, alongside a common stock offering to fund growth. Cash flow trends show volatility, with 2025 net cash flow negative at -$172.94 million but projected to rebound in 2026.
The outlook is positive due to robust earnings growth and strategic expansion, but risks include rising debt levels and integration challenges from the SEGRO deal. Analysts are bullish with a $159.22 consensus target, suggesting 15% upside, supported by institutional holdings and dividend payouts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
